𝔖 Bobbio Scriptorium
✦   LIBER   ✦

c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples

✍ Scribed by Fulvia Farabegoli; Claudio Ceccarelli; Donatella Santini; Nicola Baldini; Mario Taffurelli; Domenico Marrano; Davide Treré; Massimo Derenzini

Publisher
John Wiley and Sons
Year
1999
Tongue
French
Weight
124 KB
Volume
84
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

We investigated c-erbB-2 oncogene amplification and overexpression in 79 invasive breast carcinoma samples using fluorescence in situ hybridization (FISH) and immunohistochemistry, with the aim of studying relationships between neoplasms over-expressing c-erbB-2 with or without amplification and bio-pathological parameters used in clinical breast cancer. Nineteen samples showed amplification, and all of these were positive by immuno-histochemistry. Moderate or intense immunostaining was present in a further 22 samples without c-erbB-2 amplification and was not related to any increased number of c-erbB-2 signals: 15 samples exhibited chromosome 17 polysomy, 3 monosomy and 4 no FISH abnormalities. Thirty-eight samples were immunonegative: 18 exhibited chromosome 17 polysomy, 9 monosomy and 11 no alterations. Samples having c-erbB-2 over-expression associated with amplification showed DNA aneuploidy and hormonal receptor loss to a greater extent than those expressing c-erbB-2 without amplification or immunonegative samples ( 2 test, p ϭ 0.007, 0.008 and 0.008, respectively). The proliferation rate, detected by Ag-NOR staining, was highest in amplified samples (Kruskal Wallis test, p ϭ 0.009). Our results indicate that tumours showing both c-erbB-2 over-expression and amplification exhibit more aggressive biological characteristics than those with only over-expression or immunonegative tumours. Since both c-erbB-2 amplification and over-expression have been related to negative responses to chemotherapy and poor prognosis, these differences might have clinical implications. The combination of FISH and immuno-histochemistry may be helpful to achieve this aim.

📜 SIMILAR VOLUMES

Serial serum c-erbB-2 levels in patients
Serial serum c-erbB-2 levels in patients with breast carcinoma
✍ Gena H. Volas; Kim Leitzel; Yoshio Teramoto; Howard Grossberg; Laurence Demers; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 528 KB

## Background: Recently, the extracellular domain of the c-erbb-2 oncogene product (her-2/neu) has been reported to be elevated in the serum of one-fourth of patients with metastatic breast carcinoma. the role of serum c-erbb-2 as a tumor marker, however, is still poorly defined. the purpose of thi

New prognostic factors in nasopharyngeal
New prognostic factors in nasopharyngeal carcinoma: Tumor angiogenesis and C-erbB2 expression
✍ Debasish F. Roychowdhury; Alexander Tseng Jr.; Karen K. Fu; Vivian Weinberg; Noe 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 716 KB

## BACKGROUND. This study was conducted to determine the prognostic significance of tumor angiogenesis, c-erbB2, epidermal growth factor receptor, Ki-67, and p53 for patients with nasopharyngeal carcinoma. ## METHODS. In this retrospective study, the authors retrieved clinical data and made imm

C-erbB-2 oncoprotein in screen-detected
C-erbB-2 oncoprotein in screen-detected breast carcinoma: An immunohistological study
✍ Salma Soomro; P. Taylor; H. M. Shepard; M. Feldmann; H. D. Sinnett; S. Shousha 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 344 KB

This study was aimed at comparing screen-detected and symptomatic breast carcinomas with regard to the prevalence of positive immunostaining for c-erb-B-2 oncoprotein. Paraffin sections of 8 I breast carcinomas detected through the National Screening Programme were examined for the over-expression o

c-erbB-2 expression in FNAB smears and m
c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer
✍ G. Troncone; L. Panico; A. Vetrani; B. de Divitiis; P. Zeppa; F. Fulciniti; G. P 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 568 KB

Most of the data regarding the signijcance of c-erbB-2 oncogene expression as a prognostic marker in breast cancer have been generated in many large retrospective studies by retrieving the corresponding oncoprotein in archival parafin em bedded sections. Recent@. employing fresh breast cancer cells

Absence of microsatellite instability in
Absence of microsatellite instability in breast carcinomas with both p53 and c-erbB-2 alterations
✍ Formantici, Cristina; Orlandi, Rosaria; Ronchini, Chiara; Pilotti, Silvana; Ranz 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

Based on a previous finding that amplification of the c-erbB-2 oncogene and alteration of p53 are strongly associated in most aggressive breast tumours, the present study investigated whether microsatellite instability (MI) might also be associated with this tumour phenotype. Nine polymorphic micros